References
- Faergemann J. Baran repidemiology, clinical presentation and diagnosis of onychomycosis. Br J Dermatol 2003;149:1–4.
- Arrese JE, Piérard GE. Treatment failures and relapses in onychomycosis: a stubborn clinical problem. Dermatology 2003;207:255–60.
- Ameen M, Lear JT, Madan V, et al. British association of dermatologists’ guidelines for the management of onychomycosis 2014. Br J Dermatol 2014;171:937–58
- Sigurgeirsson B, Baran R. The prevalence of onychomycosis in the global population – a literature study. J Eur Acad Dermatol Venereol 2013;28:1480–91.
- Adiguna MS. New therapies for onychomycosis. Med Prog 2000;5:17–22.
- Hui X, Baker SJ, Wester RC, et al. In vitro penetration of a novel oxaborole antifungal (AN2690) into the human nail plate. J Pharm Sci 2007;96:2622–31.
- Ghannoum M, Isham N, Long L. In vitro antifungal activity of ME1111, a new topical agent for onychomycosis, against clinical isolates of dermatophytes. Antimicrob Agents Chemother 2015;59:5154–8.
- Takahata S, Kubota N, Takei-Masuda N, et al. Mechanism of action of ME1111, a novel antifungal agent for topical treatment of onychomycosis. Antimicrob Agents Chemother 2015;60:873–80.
- Agache P. Main skin biological constants. In: Agache P, Humbert P, eds. Measuring the skin. Berlin, Herdelberg: Spriner-Verlag; 2004:735.
- U.S. NIM Mediline Plus: Fungal nail infection – fungal nail infection is a fungus growing in and around your fingernail or toenail (updated 11/14/2014). Available from: http://www.nlm.nih.gov/medlineplus/ency/article/001330.htm [last accessed 16 Jul 2015].
- Gupchup GV, Zatz JL. Structural characteristics and permeability properties of the human nail: a review. J Cosmet Sci 1999;50:363–85.
- Palmeri A, Pichini S, Pacifici R, et al. Drugs in nails: physiology, pharmacokinetics and forensic toxicology. Clin Pharmacokinet 2000;38:95–110.
- Murdan S. The nail: anatomy, physiology, diseases and treatment. In: Murthy SN, Maibach HI, eds. Topical nail products and ungual drug delivery. Boca Raton: CRC Press, Taylor & Francis Group; 2013:1–36.
- Sugiura K, Sugimoto N, Hosaka S, et al. The low keratin affinity of efinaconazole contributes to its nail penetration and fungicidal activity in topical onychomycosis treatment. Antimicrob Agents Chemother 2014;58:3837–42.
- Gupta AK, Paquet M. Efinaconazole 10% nail solution: a new topical treatment with broad antifungal activity for onychomycosis monotherapy. J Cutan Med Surg 2014;18:151–5.
- Takei-Masuda N, Nagira Y, Kaneda K, et al. Potent antifungal activity of ME1111 against trichophyton species in the presence of keratin, abstr F-742. Abstr 55th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology; 2015, San Diego, CA.
- Dawber RP. The ultrastructure and growth of human nails. Arch Dermatol Res 1980;269:197–204.
- Kobayashi Y, Miyamoto M, Sugibayashi K, Morimoto Y. Drug permeation through the three layers of the human nail plate. J Pharm Pharmacol 1999;51:271–8.
- Hui X, Lindahl Å, Lamel S, Maibach HI. Onychopharmacokinetics of terbinafine hydrochloride penetration from a novel topical formulation into the human nail in vitro. Drug Dev Ind Pharm 2013;39:1401–7.
- Chiu WS, Belsey NA, Garrett NL, et al. Molecular diffusion in the human nail measured by stimulated Raman scattering microscopy. Proc Natl Acad Sci USA 2015;112:7725–30.
- Mertin D, Lippold BC. In-vitro permeability of the human nail and of a keratin membrane from bovine hooves: influence of the partition coefficient octanol/water and the water solubility of drugs on their permeability and maximum flux. J Pharm Pharmacol 1997;49:30–4.
- Walters KA, Flynn GL. Permeability characteristics of the human nail plate. Int J Cosmet Sci 1983;5:231–46.
- Monti D, Saccomani L, Chetoni P, et al. Hydrosoluble medicated nail lacquers: in vitro drug permeation and corresponding antimycotic activity. Br J Dermatol 2010;162:311–17.
- Baraldi A, Jones SA, Guesné S, et al. Human nail plate modifications induced by onychomycosis: implications for topical therapy. Pharm Res 2015;32:1626–33.